Literature DB >> 25225587

Combined use of non-biological artificial liver treatments for patients with acute liver failure complicated by multiple organ dysfunction syndrome.

Mao-Qin Li1, Jun-Xiang Ti1, Yun-Hang Zhu1, Zai-Xiang Shi1, Ji-Yuan Xu1, Bo Lu1, Jia-Qiong Li1, Xiao-Meng Wang1, Yan-Jun Xu1.   

Abstract

BACKGROUND: Acute liver failure (ALF) caused by viral and non-viral hepatitis is often accompanied with severe metabolic disorders, the accumulation of toxic substances and continuous release and accumulation of a large number of endogenous toxins and inflammatory mediators. The present study aimed to investigate the effects of various combined non-biological artificial liver treatments for patients with acute liver failure (ALF) complicated by multiple organ dysfunction syndrome (MODS).
METHODS: Thirty-one patients with mid- or late-stage liver failure complicated by MODS (score 4) were randomly divided into three treatment groups: plasmapheresis (PE) combined with hemoperfusion (HP) and continuous venovenous hemodiafiltration (CVVHDF), PE+CVVHDF, and HP+CVVHDF, respectively. Heart rate (HR) before and after treatment, mean arterial pressure (MAP), respiratory index (PaO2/FiO2), hepatic function, platelet count, and blood coagulation were determined.
RESULTS: Significant improvement was observed in HR, MAP, PaO2/FiO2, total bilirubin (TBIL) and alanine aminotransferase (ALT) levels after treatment (P<0.05). TBIL and ALT decreased more significantly after treatment in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.01). Prothrombin time (PT) and albumin were significantly improved only in the PE+CVVHDF and PE+HP+CVVHDF groups (P<0.05). TBIL decreased more significantly in the PE+HP+CVVHDF group than in the HP+CVVHDF and PE+CVVHDF groups (P<0.05). The survival rate of the patients was 58.1% (18/31), viral survival rate 36.4% (4/11), and non-viral survival rate 70% (14/20).
CONCLUSION: Liver function was relatively improved after treatment, but PE+HP+CVVHDF was more efficient for the removal of toxic metabolites, especially bilirubin. The survival rate was significantly higher in the patients with non-viral liver failure than in those with viral liver failure.

Entities:  

Keywords:  Artificial liver; Continuous veno-venous hemodiafiltration; Hemoperfusion; Plasma exchange; Severe acute liver failure

Year:  2014        PMID: 25225587      PMCID: PMC4163812          DOI: 10.5847/wjem.j.issn.1920-8642.2014.03.010

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  9 in total

1.  Acute renal and liver failure due to acute fatty liver of pregnancy-complicated pre-eclampsia.

Authors:  G Song; Y Li; M Li; R Xuan
Journal:  J Obstet Gynaecol       Date:  2012-10       Impact factor: 1.246

Review 2.  Artificial liver support system in China: a review over the last 30 years.

Authors:  Lan Juan Li; Yi Min Zhang; Xiao Li Liu; Wei Bo Du; Jian Rong Huang; Qian Yang; Xiao Wei Xu; Yue Mei Chen
Journal:  Ther Apher Dial       Date:  2006-04       Impact factor: 1.762

3.  Efficacy of various combined blood purification techniques for treating patients with non-viral acute liver failure.

Authors:  Mao-qin Li; Jia-qiong Li; Zai-xiang Shi; Ji-yuan Xu; Zhou Zhang; Fei Lu; Lin Li; Yan-jun Xu; Xun Mo; Bo Lu; Xiao-meng Wang; Li-li Ma; Xian-jiang Zhang; Shu-li Cheng
Journal:  Cell Biochem Biophys       Date:  2014-04       Impact factor: 2.194

4.  Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column.

Authors:  Zhao Huang; Si-Rong Wang; Wei Su; Ji-Yun Liu
Journal:  Ther Apher Dial       Date:  2010-12       Impact factor: 1.762

5.  High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E.

Authors:  Manasi Majumdar; Radhakanta Ratho; Yogesh Chawla; Mini P Singh
Journal:  Liver Int       Date:  2013-05-19       Impact factor: 5.828

6.  Clinical epidemiology of fulminant hepatitis in Japan.

Authors:  Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Hepatol Res       Date:  2008-11       Impact factor: 4.288

7.  [Treatment of multiple organ dysfunction syndrome by Xuebijing Injection: a clinical research].

Authors:  Kai Fang; Xiao-Ling Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2013-02

8.  Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression.

Authors:  Zhen Zheng; Xu Li; Zhiliang Li; Xiaochun Ma
Journal:  Exp Ther Med       Date:  2013-07-31       Impact factor: 2.447

9.  Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome.

Authors:  Xiao-Ling Wu; Ding Long; Li Yu; Jun-Hui Yang; Yuan-Chao Zhang; Feng Geng
Journal:  World J Emerg Med       Date:  2013
  9 in total
  1 in total

1.  Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure.

Authors:  Jia Yao; Shuang Li; Li Zhou; Lei Luo; Lili Yuan; Zhongping Duan; Jun Xu; Yu Chen
Journal:  J Clin Apher       Date:  2019-02-13       Impact factor: 2.821

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.